Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01392963 · ClinicalTrials.gov registry record · Phase 2
The Treatment of Depression With Botulinum Type A Toxin
A Phase 2 study, sponsored by Seton Healthcare Family.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01392963 is a Phase 2 study that has completed, run by Seton Healthcare Family. The registered enrollment target is 30 participants.
The verdict
NCT01392963, a Phase 2 study, has completed, sponsored by Seton Healthcare Family.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
A 24-week Randomized, Double-blind study treating people who suffer from depression who also have moderate to severe frown lines in forehead region with Botox injections. Subjects participating will have their photos taken and complete a questionnaire regarding their depression. They will see a psychiatrist at every visit who will assess their depression.
Interventions
- DRUG Placebo
- DRUG botulinum toxin type A neurotoxin complex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01392963
The ClinicalTrials.gov registry entry for NCT01392963 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seton Healthcare Family, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01392963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01392963 about?
NCT01392963 is a clinical study titled "The Treatment of Depression With Botulinum Type A Toxin". A 24-week Randomized, Double-blind study treating people who suffer from depression who also have moderate to severe frown lines in forehead region with Botox injections. Subjects participating will have their photos taken and complete a questionnaire regarding their depression. They will see a psyc...
What is the current status of trial NCT01392963?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2011-07. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01392963?
The interventions under investigation include: Placebo (DRUG), botulinum toxin type A neurotoxin complex (DRUG).
Who is sponsoring clinical trial NCT01392963?
This trial is sponsored by Seton Healthcare Family, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.